Clinical trial · Observational
Persistent Pain After Breast Cancer Treatment With Docetaxel
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer treatment is for many patients followed by sequelae, such as persistent pain, sensory disturbances, lymphedema and reduced physical function. These undesired consequences of the treatment are a major clinical problem, with persistent pain affecting 25-60%, sensory disturbances 20-80%, lymphedema 2-86% and reduced physical function 13-28% of patients. Development of persistent pain after breast cancer treatment, involves a complex pathophysiology that involves pre-, intra- and postoperative factors. Several risk factors for the development of persistent pain after breast cancer treatment have been identified; young age, psychosocial factors, surgical procedure and radiation therapy. Neurotoxicity is a well know attribute of many chemotherapeutic agents, such as taxanes. The purpose of this nationwide study is to retrospectively examine a cohort of breast cancer patients treated with docetaxel, to clarify if docetaxel may influence the prevalence and intensity of persistent pain and other sequelae.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Lymphedema | — | UNRESOLVED | — |
| Neuralgia | — | UNRESOLVED | — |
| Pain, Postoperative | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients treated with docetaxel
- description
- Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
Primary outcomes (1)
- measure
- Docetaxel as a risk factor for development of persistent pain
- timeFrame
- Between 2-3 years post surgery
Secondary outcomes (1)
- measure
- Prevalence of persistent pain, sensory disturbances, lymphedema and functional limitations
- timeFrame
- Between 2-3 years post surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Treated for primary breast cancer in Denmark 2007-2008 * Age between 18-80 years * No recurrent cancer * Female Exclusion Criteria: * Previous breast surgery same side (including plastic and reconstructive surgery) * Bilateral breast surgery * Recurrent cancer or metastatic cancer
References
Publications (0)
Data not yet available